Bosshard joins the company as it looks to advance its insulin delivery technology. San Diego-based Modular Medical develops pump technology designed for “almost-pumpers.” It targets adults with a user-friendly, affordable design. Modular Medical’s current pump, the MODD1, won FDA clearance nearly a year ago. It has microfluidics technology that allow for the low-cost pumping of insulin.
The company announced earlier this year that it began converting its manufacturing line to prepare for production of Pivot, its next-generation insulin patch pump technology.
Bosshard, meanwhile, brings two decades of scaling similar tubeless insulin delivery systems across Europe and beyond. That includes 16 years spent at Ypsomed, where he helped lead launches for Insulet’s Omnipod under a now-expired distribution agreement, as well as Ypsomed’s own YpsoPump.
Modular Medical says Bosshard will drive its global strategy, leveraging his success in launching blockbuster products. His appointment comes at a vital time as the company advances Pivot through U.S. and European regulatory processes. The company believes Bosshard’s appointment can help accelerate its planned international rollout as it seeks to penetrate those markets.
“David’s addition to our team is a game-changer for Modular Medical’s international ambitions,” said Jeb Besser, CEO of Modular Medical. “His success in scaling the Omnipod and launching YpsoPump with international users aligns perfectly with our mission to make affordable, intuitive patch pumps accessible worldwide. We’re excited to harness his expertise in launching our Pivot product internationally, as we seek to access high-growth markets outside the U.S. and evaluate each for direct and indirect distribution opportunities.”
